Bayer donates one million euros for hospitals in Lombardy

  • Chairman of the Board of Management, Baumann: Our emergency aid is designed to help support hospitals and hospital staff during the crisis.


Leverkusen, March 18, 2020 Bayer is supporting hospitals in Lombardy, Italy, with a donation of one million euros. The money is being added to an aid fund that the regional authorities in Lombardy have set up to help procure urgently needed equipment for intensive care units in hospitals with the greatest needs. Our colleagues in Italy are working with unbelievable commitment to maintain the supply of our medicines. On top of that, our emergency aid is designed to help support hospitals and hospital staff during the crisis, says Werner Baumann, Chairman of the Board of Management of Bayer AG.

Lombardy is by far the region of Italy worst affected by the corona pandemic. Hospitals there are reaching the limits of their capacity.

Besides Italy, Bayer has already sent considerable financial and material support to China to help contain the pandemic. Bayer will continue to provide affected regions and countries with rapid and unbureaucratic assistance as part of its corporate social responsibility.


About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to


Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.